Athenex Stock News

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Anaptys Discontinues Phase 2 Study Of Imsidolimab In Acne Anaptys Bio, Inc. (NASDAQ: ANAB) said the Ph

Companies Reporting Before The Bell • IDEAYA Biosciences (NASDAQ: IDYA ) is likely to report quarterly loss at $0.31 per share on revenue of $8.98 million. • Citi Trends (NASDAQ: CTRN ) is projected to report quarterly earnings at $1.12 per share on revenue of $250.54 million. • Precision BioSciences (NASDAQ: DTIL ) is likely to report quarterly loss at $0.47 per share on revenue of $7.75 million. • SPX FLOW (NYSE: FLOW ) is estimated to report quarterly loss at $0.17 per share on revenue of $10.88 million. • Brickell Biotech (NASDAQ: BBI ) is likely to report quarterly loss at $0.08 per share on revenue of $150.00 thousand. • Imara (NASDAQ: IMRA ) is expected to report earnings for its fourth quarter. • Gamida Cell (NASDAQ: GMDA ) is estimated to report earnings for its fourth quarter. • Syros Pharmaceuticals (NASDAQ: SYRS ) is likely to report quarterly loss at $0.47 per share on revenue of $4.80 million. • Global X Guru Index ETF (NYSE: GURU ) is likely to report quarterly loss at $0.

Athenex (NASDAQ:ATNX) is scheduled to announce Q4 earnings results on Tuesday, March 15th, before market open.The consensus EPS Estimate is -$0.32 (+39.6% Y/Y) and the consensus…

BUFFALO, N.Y., March 14, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the

紐約水牛城, March 14, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX) 是一家致力於研究、開發和商業化治療癌症和相關疾病新療法的的全球生物製藥公司。今天宣

Athenex, Inc. (NASDAQ:ATNX) with the stream of 3.34% also noticed, India BitNile Holdings, Inc. (AMEX:NILE) encountered a rapid change of -2.22% in the last hour of Monday’s trading session. Athenex, … The post Blustering Stock: Athenex, Inc. (NASDAQ:ATNX), BitNile Holdings, Inc. (AMEX:NILE) appeared first on Stocks Equity .

紐約水牛城, March 07, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX) 是一家致力於研究、開發和商業化治療癌症和相關疾病新療法的的全球生物製藥公司。今天宣

Athenex Inc. (NASDAQ:ATNX) concluded the trading at $0.86 on Friday, February 25 with a rise of 7.31% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $0.81 and 5Y monthly beta was reading 0.63 with its price kept floating in the range … Athenex Inc. (ATNX) Recovers 18.87% From Low: Are We There Yet? Read More »

Athenex, Inc. (NASDAQ:ATNX) with the stream of 4.53% also noticed, India BRF S.A. (NYSE:BRFS) encountered a rapid change of 2.47% in the last hour of Tuesdays trading session. Athenex, Inc. The post Exceptional Stock in Review: Athenex, Inc. (NASDAQ:ATNX), BRF S.A. (NYSE:BRFS) appeared first on Stocks Equity .

Athenex (ATNX) has appointed Joe Annoni as its new chief financial officer and officer of the company, effective immediately.Prior to joining Athenex, Annoni served as Managing

紐約水牛城, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX)作為一家全球生物製藥公司，致力發現與開發治療癌症及相關疾病的新療法及將其商業化�

BUFFALO, N.Y., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies f

BUFFALO, N.Y., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that Johnson Lau, CEO and Board Chairman, and Daniel Lang, President, Athenex Cell Therapy, will present at the 11 th Annual SVB Leerink Global healthcare Conference on Thursday, February 17, 2022, at 3:00 P.M. ET.

BUFFALO, N.Y., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for

BUFFALO, N.Y., Jan. 12, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies f